ERBB3 G284R

CI-VAR-00001697Explore in graph →ClinVar 376167 CIViC 703

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
ERBB3 G284R	Lapatinib + TrastuzumabCombination	Predictive	C	Supports Sensitivity Response	4	submitted	EID7244 A 46-year old woman with metastatic breast cancer after 2 lines of systemic therapy (doxorubicin/cyclophosphamide and docetaxel/capecitabine) was found to harbor a ERBB3 G284R mutation in the primary … (full text at CIViC) PMID 25953157 · Bidard et al., 2015 · Open in CIViC	civic
Malignant Neoplasm2
ERBB3 G284R	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID9683 Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the G284R mutation in the presence of ERBB2 resulted in increased anchorage independent gr…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Transitional Cell Carcinoma1
ERBB3 G284R	Afatinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1748 In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or… (full text at CIViC) PMID 27044931 · Choudhury et al., 2016 · Open in CIViC	civic

Unmapped disease1unmapped disease
ERBB3 G284R	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID9682 Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the G284R mutation in the presence of ERBB2 resulted in increased anchorage independent gr… (full text at CIViC) PMID 23680147 · Jaiswal et al., 2013 · Open in CIViC	civic